INTRODUCTION {#s1}
============

Gastric cancer (GC) is the fourth most common malignancy and the second leading cause of cancer related death worldwide \[[@R1]\]. Surgical resection is the only curative option, but outcomes are poor \[[@R2]\]. Preoperative radiotherapy (Pre-RT) offers multiple advantages. Trials from Europe and Asia have been conducted to determine the feasibility of Pre-RT for GC \[[@R3]\]. Several randomized studies and meta-analysis have demonstrated a survival benefit for Pre-RT in patients with GC compared with surgery alone \[[@R3]--[@R5]\].

Lymph node (LN) metastases indicate worse treatment response and poorer survival. The American Joint Committee on Cancer (AJCC) successively established standards for LN stage based on metastatic LNs in the anatomical positions and the number of LN metastasis \[[@R2]\]. While the node-positive patients with GC are heterogeneous and the prognosis of these patients cannot be stratified by the node-stage only \[[@R6], [@R7]\]. Therefore, the concept of negative lymph node (NLN) counts attracted attention recently. It can serve as a prognostic indicator in various cancers, such as cervical \[[@R8]\], breast \[[@R9]\], esophagus \[[@R10]\] and GC \[[@R11]\]. However, Pre-RT can yield tumor downstaging, reduce the burden of residual microscopic disease at surgery and reduce the number of LNs retrieved in operation \[[@R3]\]. With the decreased LNs retrieval, the prognostic value of the LN count might also diminish \[[@R12]\]. Thus, it is unclear whether NLN still has prognostic value for survival of patients with GC who received Pre-RT. The purpose of this study was to assess the association between NLN count and survival of patients with GC who received Pre-RT. In order to get convincing results in a larger series of patients, we used the SEER (Surveillance, Epidemiology and End Results)-registered database to analyze this association, and determine the optimal cutoff value of NLN count.

RESULTS {#s2}
=======

Patient characteristics in SEER database {#s2_1}
----------------------------------------

In our study period from 2004 to 2013, a total of 1,346 patients with GC who received Pre-RT met our selection criteria, including 1,130 male and 216 female. The median age of patients was 62 years (20 - 93). There were 738 patients with stage ypN0, 297 with stage ypN1, 214 with stage ypN2 and 97 with stage ypN3. The demographics and pathological features of patients are summarized in Table [1](#T1){ref-type="table"}. The ypN stage was closely correlated with sex, year of diagnosis, grade, histologic type, and ypT stage (P \< 0.05).

###### Demographics and pathological features of patients with GC who received Pre-RT

  Variable                          N (1346)   ypN0         ypN1         ypN2         ypN3        χ2       P value
  --------------------------------- ---------- ------------ ------------ ------------ ----------- -------- ---------
  Sex                                                                                                      
   Male                             1130       595 (52.7)   267 (23.6)   189 (16.7)   79 (7.0)    17.347   0.001
   Female                           216        143 (66.2)   30 (13.9)    25 (11.6)    18 (8.3)             
  Age                                                                                                      
   \<60                             526        267 (50.8)   121 (23.0)   93 (17.7)    45 (8.6)    6.854    0.077
   ≥60                              820        471 (57.4)   176 (21.5)   121 (14.8)   52 (6.3)             
  Year of diagnosis                                                                                        
   2004-2008                        495        259 (52.3)   114 (23.0)   73 (14.7)    49 (9.9)    9.756    0.021
   2009-2013                        851        479 (56.3)   183 (21.5)   141 (16.6)   48 (5.6)             
  Race                                                                                                     
   White                            1202       662 (55.1)   267 (22.2)   186 (15.5)   87 (7.2)    3.846    0.698
   Black                            59         29 (49.2)    11 (18.6)    13 (22.0)    6 (10.2)             
   Others                           85         47 (55.3)    19 (22.4)    15 (17.6)    4 (4.7)              
  Grade                                                                                                    
   Well-moderately differentiated   487        311 (63.9)   110 (22.6)   52 (10.7)    14 (28.7)   71.162   \<0.001
   Poor-undifferentiated            728        337 (46.3)   165 (22.7)   153 (21.0)   73 (10.1)            
   Unkown                           131        90 (68.7)    22 (16.8)    9 (6.9)      10 (7.6)             
   Histologic type                                                                                         
   Adenocarcinoma                   1113       626 (56.2)   245 (22.0)   175 (15.7)   67 (6.0)    23.931   0.001
   Signet ring cell carcinoma       159        70 (44.0)    33 (20.8)    33 (20.8)    23 (14.5)            
   Others                           74         42 (56.8)    19 (25.7)    6 (8.1)      7 (9.5)              
   ypT Stage                                                                                               
   T1                               136        102 (75.0)   20 (14.7)    12 (8.8)     2 (1.5)     44.418   \<0.001
   T2                               182        110 (60.4)   46 (25.3)    17 (9.3)     9 (4.9)              
   T3                               576        309 (53.6)   121 (21.0)   95 (16.5)    51 (8.9)             
   T4                               452        217 (48.0)   110 (24.3)   90 (19.9)    35 (7.7)             

The optimal cutoff value for NLNs determined by X-tile program {#s2_2}
--------------------------------------------------------------

To assess the influence of different NLN count on cancer-specific survival (CSS), we analyzed the individual result using different NLN count ranging from 1 to 24. The 3-year and 5-year CSSs were calculated for patients with N (NLNs number) or more nodes and less than N nodes. As shown in Table [2](#T2){ref-type="table"}, NLN count was a prognosis factor for number ranging from 1 to 18. The 5-year CSS rate increased from 14.5% to 46.5%. Next X-tile plots were constructed and the maximum χ2 log-rank value of 26.872was produced (Figure [1](#F1){ref-type="fig"}, P \< 0.001), applying 12 as the optimal cutoff value to divide the cohort into high and low risk subsets in terms of CSS. There was a significant difference in 3-year and 5-year CSS between two subsets (42.3% v.s. 56.2%, and 30.5% v.s. 40.8%, respectively).

###### Univariate analysis of the influence of different NLN count on CSS in patients with GC who received Pre-RT

  Total NLNs   No.    3-year CCS   5-year CCS   Log rank χ2 test   P value   Total NLNs   No.    3-year CCS   5-year CCS   Log rank χ2 test   P value
  ------------ ------ ------------ ------------ ------------------ --------- ------------ ------ ------------ ------------ ------------------ ---------
  \<1          27     27.2%        14.5%        12.171             \<0.001   \<13         738    42.3%        30.5%        27.123             \<0.001
  ≥1           1319   48.8%        38.3%                                     ≥13          608    56.2%        48.1%                           
  \<2          69     24.6%        17.4%        22.697             \<0.001   \<14         798    43.1%        31.8%        21.641             \<0.001
  ≥2           1277   49.7%        39.0%                                     ≥14          548    56.7%        48.0%                           
  \<3          109    27.5%        17.9%        29.529             \<0.001   \<15         844    43.4%        32.5%        21.094             \<0.001
  ≥3           1237   50.3%        39.7%                                     ≥15          502    57.6%        48.2%                           
  \<4          167    32.3%        24.5%        23.963             \<0.001   \<16         888    43.6%        32.5%        23.181             \<0.001
  ≥4           1179   50.8%        39.9%                                     ≥16          458    58.5%        50.0%                           
  \<5          223    37.0%        27.4%        18.418             \<0.001   \<17         938    44.5%        33.6%        16.224             \<0.001
  ≥5           1123   50.7%        40.0%                                     ≥17          408    58.5%        49.4%                           
  \<6          275    39.0%        29.3%        16.654             \<0.001   \<18         981    45.7%        35.1%        7.492              0.006
  ≥6           1071   50.9%        40.2%                                     ≥18          365    56.8%        46.5%                           
  \<7          356    39.5%        29.5%        19.387             \<0.001   \<19         1027   46.6%        36.1%        3.552              0.059
  ≥7           990    51.7%        41.0%                                     ≥19          319    55.2%        44.4%                           
  \<8          426    39.9%        29.8%        20.603             \<0.001   \<20         1061   47.0%        36.2%        3.248              0.071
  ≥8           920    52.5%        41.9%                                     ≥20          285    54.3%        45.4%                           
  \<9          483    40.0%        28.3%        26.671             \<0.001   \<21         1094   47.2%        36.5%        2.188              0.139
  ≥9           863    53.3%        44,1%                                     ≥21          252    54.7%        45.2%                           
  \<10         554    41.2%        29.0%        25.278             \<0.001   \<22         1130   47.4%        36.5%        2.868              0.090
  ≥10          792    53.6%        45.0%                                     ≥22          216    54.7%        46.9%                           
  \<11         611    41.7%        30.0%        24.380             \<0.001   \<23         1152   47.6%        36.9%        1.473              0.225
  ≥11          735    54.2%        45.4%                                     ≥23          194    53.6%        44.9%                           
  \<12         663    42.6\^       31.0%        21.310             \<0.001   \<24         1162   47.7%        37.0%        1.189              0.276
  ≥12          683    54.3%        45.4%                                     ≥24          184    53.2%        43.9%                           

![X-tile analysis of survival data from the SEER registry\
X-tile analysis was performed using patients' data from the SEER registry, equally divided into training and validation sets. X-tile plots of the training sets are shown with plots of matched validation sets shown in the smaller inset **A**. The optimal cut-point highlighted by the black circle in the left panels is shown on a histogram of the entire cohort **B**., and a Kaplan-Meier plot **C**. P values were determined using the cutoff point defined in the training set and applying it to the validation set. (The optimal cutoff value for NLN count is 12, χ^2^= 26.872, P \< 0.001.)](oncotarget-08-46946-g001){#F1}

Nomograms for predicting survival of patients with GC who received Pre-RT {#s2_3}
-------------------------------------------------------------------------

According to univariate analysis, NLN count (P\<0.001), sex (P=0.018), year of diagnosis (P=0.045), grade (P=0.012), histologic type (P\<0.001) and ypN stage (P\<0.001) were associated with poor survival. In multivariate Cox analysis (Table [3](#T3){ref-type="table"}), grade, ypN stage and NLN counts were independently prognostic factors. A higher number of NLN counts showed a favorable effect on survival (HR=1.375, 95% CI: 1.166-1.621, P\< 0.001).

###### Univariate and multivariate survival analysis for evaluating the influence of NLNs on CSS

  Variable                          3-year CCS   5-year CCS   Univariate analysis   Multivariate analysis                              
  --------------------------------- ------------ ------------ --------------------- ----------------------- -------------------------- -----------
  Sex                                                         5.596                 0.018                                              **0.069**
   Male                             47.0%        36.3%                                                      **Ref**.                   
   Female                           55.3%        45.5%                                                      **1.253 (0.998\~1.575)**   
  Age                                                         0.728                 0.394                                              NI
   \<60                             49.9%        38.9%                                                                                 
   ≥60                              47.3%        37.1%                                                                                 
  Year of diagnosis                                           4.0                   0.045                                              0.389
   2004-2008                        45.9%        34.9%                                                      Ref.                       
   2009-2013                        50.5%        39.6%                                                      1.702 (0.908\~1.264)       
  Race                                                        2.461                 0.292                                              NI
   White                            47.7%        37.4%                                                                                 
   Black                            49.1%        36.2%                                                                                 
   Others                           59.0%        45.9%                                                                                 
  Grade                                                       20.972                \<0.001                                            0.012
   Well-moderately differentiated   55.7%        43.8%                                                      Ref.                       
   Poor-undifferentiated            43.9%        31.6%                                                      0.886 (0.635-0.981)        
   Unkown                           41.0%        31.1%                                                      1.233 (0.938-1.465)        
   Histologic type                                            16.316                \<0.001                                            0.091
   Adenocarcinoma                   50.8%        40.8%                                                      Ref.                       
   Signet ring cell carcinoma       34.0%        21.6%                                                      1.003 (0.721\~1.395)       
   Others                           44.4%        30.4%                                                      1.298 (0.896\~1.878)       
  ypT Stage                                                   3.338                 0.342                                              NI
   T1                               50.4%        44.8%                                                                                 
   T2                               52.1%        35.4%                                                                                 
   T3                               49.8%        37.5%                                                                                 
   T4                               44.5%        36.7%                                                                                 
  ypN Stage                                                   113.780               \<0.001                                            \<0.001
   ypN0                             61.3%        49.2%                                                      Ref.                       
   ypN1                             37.3%        28.8%                                                      0.366 (0.280\~0.480)       
   ypN2                             30.3%        22.4%                                                      0.625 (0.470\~0.833)       
   ypN3                             20.5%        10.5%                                                      0.714 (0.529\~0.963)       
  No. of NLNs                                                 27.123                \<0.001                                            \<0.001
   \<13                             42.3%        30.5%                                                      Ref.                       
   ≥13                              56.2%        48.1%                                                      1.375 (1.166\~1.621)       

In order to predict CSS, the nomogram was established by multivariate Cox regression model according to all significantly independent factors including grade, ypN stage and NLN counts (Figure [2](#F2){ref-type="fig"}). Nomogram could be interpreted by summing up the points assigned to each variable, which was indicated at the top of scale. The total points could be converted to predicted 3-year and 5-year CSS to obtain the probability of death. The Harrell\'s C-index for CSS prediction was 0.630 (95% CI: 0.605--0.655). Calibration curves for the nomogram revealed no deviations from the reference line and no need of recalibration (Figure [2](#F2){ref-type="fig"}).

![Nomogram for predicting 3-year and 5-year CSS of patients with GC who received Pre-RT\
**A**. Nomograms with clinicopathological characteristics and NLN count. Nomograms could be interpreted by summing up the points assigned to each variable, which was indicated at the top of scale. The total points could be converted to predicted 3-year and 5-year probability of death for patients with GC who received Pre-RT in the lowest scale. The Harrell\'s C-index for CSS prediction was 0.630 (95% CI: 0.605--0.655). **B and C**. Calibration curves using nomograms with clinicopathological characteristics and NLNs for predicting 3-year and 5-year CSS. The X-axis was nomogram-predicted CSS and Y-axis was observed CSS. The reference line was 45° and indicated perfect calibration.](oncotarget-08-46946-g002){#F2}

Subgroup analysis for evaluating the effect of NLN count according to TNM stage {#s2_4}
-------------------------------------------------------------------------------

According to the AJCC-7 GC staging system, patients with LNs metastases were divided into three subgroups including stage ypI, ypII and ypIII. We then further analyzed the effects of NLN on survival in each subgroup. As shown in Table [4](#T4){ref-type="table"}, NLN count was an independently prognostic factor in the stage ypII (χ2= 8.300, P=0.004) and stage ypIII subgroups (χ2= 13.404, P\<0.001), but not in the stage ypI subgroup (χ2= 1.904, P=0.168) on both univariate and multivariate analysis (Figure [3](#F3){ref-type="fig"}, P \< 0.001).

###### Univariate and multivariate survival analysis for evaluating the influence of the NLN count on CSS in three subgroups

  Variable      3-year CCS   5-year CCS   Univariate analysis   Multivariate analysis                          
  ------------- ------------ ------------ --------------------- ----------------------- ---------------------- -------
  Stage ypI                                                                                                    
  No. of NLNs                             1.904                 0.168                   NI                     
   \<13         56.3%        45.5%                                                                             
   ≥13          65.0%        55.5%                                                                             
  Stage ypII                                                                                                   
  No. of NLNs                             8.300                 0.004                                          0.019
   \<13         48.3%        33.0%                                                      Reference              
   ≥13          60.3%        52.0%                                                      1.316 (1.045\~1.656)   
  Stage ypIII                                                                                                  
  No. of NLNs                             13.404                \<0.001                                        0.001
   \<13         27.7%        20.0%                                                      Reference              
   ≥13          38.9%        32.8%                                                      1.641 (1.238\~2.176)   

![Log-rank tests of CSS comparing patients with NLNs (\< 13 VS ≥13) for A. stage ypI: χ^2^ = 1. 904, P = 0.618; B. stage ypII: χ^2^ = 8.300, P = 0.004; and C. stage ypIII: χ^2^ = 13.404, P \< 0.001.](oncotarget-08-46946-g003){#F3}

DISCUSSION {#s3}
==========

Despite a decreasing incidence of GC in some developed countries over the past decade, about 1,000, 000 new cases are diagnosed each year globally, with the 5-year survival less than 30% \[[@R13]\]. LN metastasis is considered one of the most significant prognostic factors \[[@R14]\]. Yet, the number of positive LN is often affected by many facts such as neoadjuvant therapy, and the number of LN retrieved and inspected \[[@R3], [@R15]\]. Once the LN retrieved is not enough, the prediction of survival would be inaccurate. The intended purpose of Pre-RT is tumor down-staging by decreasing the primary tumor bulk and reducing the burden of residual associated LN metastases at surger \[[@R3]\]. It has been reported that Pre-RT may cause radiation-induced lymphocyte destruction and stromal fibrosis resulting in alterations of the morphology of the LNs, making LN detection during operation more difficult \[[@R3]\]. Some researchers also found that a decreased LN count after Pre-RT was related to good survival \[[@R4], [@R5]\].

NLN count has a unique advantage that it is little influenced by the number of LN retrieved \[[@R11]\]. The more NLN count is, the better the survival would be. It has been reported that the NLN count was a key factor for the survival of patients with GC after curative resection \[[@R16]\]. In this study, we found that the NLN count was an independent prognosis factor for patients with GC who received Pre-RT. And we also identified the optimal cutoff value for NLN count as 12. Obviously, NLN count is a good supplement for LN stage and TNM stage on evaluating prognosis, especially for patients with advanced GC (stage ypII and ypIII) who received Pre-RT. Until now, there has been no report confirming the mechanism of NLNs influencing on the prognosis of GC. It is suggested that lymphatic micrometastasis is a key etiology of recurrence and metastasis after resection of GC \[[@R17]\]. LN micrometastasis, is common in nodes with the size ranging from 0.2 mm to 2.0 mm which determined to be negative by HE staining, but positive for cytokeratin by immunohistochemicalstaining \[[@R18]\]. It is difficult to find lymphatic micrometastasis during operation. Because the NLN count has potential to reflect the dissection of lymphatic micrometastasis, we can retrieve more NLNs to reduce the residual micrometastases, in order to improve the prognosis of GC. In this study, subgroup analysis showed that NLN count was an independent prognosis factor for GC patients with stage ypII and ypIII, but not for patients with stage ypI. One possible explanation might be that less LN is retrieved in GC patients with stage ypI, thus the prediction of survival would be less accurate.

The results of this study have several potential limitations. First, the SEER database does not include information of therapeutic options such as radical resection or palliative therapy, detailed information of chemotherapy, recurrence and metastasis, which may also impact patients' prognosis \[[@R11]\]. Especially the preoperative chemotherapy has already been recognized as effective for latent lymph node micrometastasis \[[@R19]\]. It actually may have great impact on the prognosis and NLN count \[[@R20]\]. Thus, additional trials will be needed to investigate whether NLN still has prognostic value count on survival of patients with GC who received chemotherapy. Second, different operative approaches, doctors and even pathologist would affect the detective rate of total LN and metastatic LN, but the SEER do not include these information \[[@R12]\]. Third, preoperative clinical grading and the information about tumor and LN recession response to treatment are still uncertain. All of these factors may influence the curative effect of neoadjuvant therapy and the survival.

In conclusion, our analysis of the SEER database revealed that NLN count (with an optimal cutoff value of 12) in was an independent prognosis factor for patients with GC who received Pre-RT. Subgroup analysis showed that NLN count provided more accurate prognostic information especially for patients with advanced GC (stage ypII and ypIII). Nomograms based on CSS could be recommended as practical models to evaluate prognosis.

MATERIALS AND METHODS {#s4}
=====================

Patient selection {#s4_1}
-----------------

All data was obtained from the SEER database. The current SEER database consists of 18 population-based cancer registries that represent approximately 26% of the population in the United States. The SEER data contain no identifiers and are publicly available for studies of cancer-based epidemiology and health policy.

The National Cancer Institute\'s SEER\*Stat software (Surveillance Research Program, National Cancer Institute SEER\*Stat software, [www.seer.cancer.gov/seerstat](http://www.seer.cancer.gov/seerstat) (Version 8.3.2), was used to identify patients whose pathological diagnosis as GC between 2004 and 2013. Only patients who underwent preoperative radiotherapy and surgical treatment with age of diagnosis more than 18 years were included. Histological type were limited to adenocarcinoma (8140/3, 8144/3, 8255/3, 8211/3, 8260/3, 8263/3), signet ring cell carcinoma (8490/3) and other uncommon pathological classification. Patients were excluded if they had multiple primary malignant neoplasms, incomplete TNM staging, with distant metastasis (M1), no evaluation on LNs, died within 30 days after surgery or information on CSS and survival months unavailable.

Age, sex, year of diagnosis, race, grade, T stage, total number of LN examined, number of positive LNs and survival time was assessed. TNM classification was restaged according to the criteria described in the AJCC Cancer Staging Manual (7th edition, 2010).

Statistical analysis {#s4_2}
--------------------

The NLNs cutoff points were determined using the X-tile program, which identified the cutoff with the minimum P values from log-rank χ2 statistics for the categorical NLNs in terms of survival. Association of ypN stage with clinicopathological parameters was analyzed by chi-square (χ2) test. Survival curves were generated using Kaplan-Meier estimates, and the differences were analyzed by log-rank test. Cox regression models were built for analysis of risk factors for survival outcomes. Nomogram on CSS was established according to all significant factors. Statistical analyses were performed using the statistical software package SPSS for Windows, version 19.0 (SPSS Inc, Chicago, IL, USA). Results were considered statistically significant when a two-sided p values of less than 0.05.
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